Correlation of the subpopulation co-expressing NT and NT1 receptor with the major prognosis factors.

<p>Correlation of the subpopulation co-expressing NT and NT1 receptor with the major prognosis factors.</p

NTSR1 expression in IDCs and global survival duration.

<p>Kaplan-Maier analysis for global survival duration in both groups with low (<80%) and high (≥80%) NTSR1 expression. Probability of overall death for patients with high NTSR1 expression (n = 38) versus patients with low NTSR1 expression (n = 68).</p

Neurotensin expression in IDCs.

<p>a) NTS immunohistochemistry was performed on IDCs, ductal (1) and invasive (2) components, magnification 200× for (1) and 400× for (2). b) NTS and NTSR1 transcripts in IDCs. One µg of total RNA from 11 patients with IDCs were reverse-transcribed, and specific PCR was performed for NTS, NT-1 receptor, or GAPDH (control). The SBR grade is indicated below each line. c) Example of NTS and NTSR1 regional co-localization by immunohistochemistry for NTS (right) and NTSR1 (left) at the original magnification 400×.</p

Prognosis factors and deaths stratified by NT expression in the ductal and invasive components of IDCs.

<p>Prognosis factors and deaths stratified by NT expression in the ductal and invasive components of IDCs.</p

Prognosis factors and deaths stratified by NT-1 receptor expression in the invasive component of IDCs.

<p>Prognosis factors and deaths stratified by NT-1 receptor expression in the invasive component of IDCs.</p

Neurotensin expression in normal breast tissue.

<p>a) <i>Left</i>, one µg of total RNA from HBEC or whole gland were reverse-transcribed and a PCR experiment specific for NTS was performed. <i>Right</i>, <i>o</i>ne µg of total RNA from HBEC cells (control, treated with 10 nM estradiol (E2) with or without 1 µM ICI 182780) was reverse-transcribed. A PCR experiment was performed using specific primers for NTS and GAPDH. b) Normal duct exposed to NTS antibody at 1/500 dilution (1), after pre-incubation with the antigen peptide for 2 h at 10 nM (2), or without primary antibody (3), and lobule exposed to NTS antibody (4). Normal tissue exposed to NTS antibody at 1/500 dilution adjacent to tumor duct (5), lobule (6). The original magnification was 200×.</p

Patients clinical characteristics.

<p>SBR; Scarff Bloom and Richardson, n = number of patients, SD = standard deviation.</p